Revenue and profits saw double-digit growth year-over-year, driven by robust domestic and overseas sales, increased royalty and one-time income, and strong performance in oncology and specialty products. The company maintained high free cash flow and equity ratios, with a positive outlook for the full year.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.